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Abstract
Background: Multi drug resistance of Mycobacterium tuberculosis (M. tuberculosis) remains a major
threat to public health, reinforced by recent reports about the clinical course of patients infected
with extensively drug resistant (XDR) strains in South Africa. There is little information about the
clinical course of XDR tuberculosis patients in industrialised countries.
Methods: We evaluated all isolates of M. tuberculosis, in which drug susceptibility testing was
performed at our institution since 1997, for multi and extensive drug resistance. Clinical courses
of patients infected by strains fulfilling the recently revised criteria for XDR tuberculosis were
analysed.
Results: Four XDR M. tuberculosis isolates were identified. All patients had immigrated to Germany
from Russia, Georgia, and former Yugoslavia and none were infected by the human
immunodeficiency virus. All patients where treated for tuberculosis for 5.5 to 15 years and for
XDR tuberculosis for 1.9 to 2.5 years. They received inhospital treatment in Germany for 11
months, 4.5 years and twice for 6 years. Non-compliance was an important factor in all four
patients, three patients had to be treated in Germanys only locked facility for tuberculosis
treatment. One patient with XDR tuberculosis died, one patient had still open pulmonary
tuberculosis at last contact and 2 patients were cured.
Conclusion: Cases of XDR tuberculosis have been treated in our region for several years. Even
in a high income setting, XDR tuberculosis has a tremendous impact on quality of live, outcome
and the total cost. All reasonable efforts to prevent the spread of XDR tuberculosis must be made
and maintained.
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Background
Tuberculosis (TB) remains one of the major causes of
death from a single infectious agent worldwide. The emer-
gence of multi drug resistance, defined as resistance to at
least rifampin (RMP) and isoniazid (INH) is of great con-
cern. Recently, reports of strains with extensively drug
resistant (XDR) TB have been described and the question
was raised, whether we enter the post-antibiotic era [1-4].
In October 2006 the WHO Global Task Force on XDR-TB
met in Geneva, Switzerland, and approved the following
revised laboratory case definition of XDR-TB: "TB show-
ing resistance to at least rifampin and isoniazid, which is
the definition of multi drug resistant (MDR) TB, in addi-
tion to any fluoroquinolone, and to at least 1 of the 3 fol-
lowing injectable drugs used in anti-TB treatment:
capreomycin, kanamycin and amikacin" [5]. A report of
53 XDR-TB patients with a high prevalence of human
immunodeficiency virus (HIV) infection from rural South
Africa, showed an alarming case fatality rate of almost
100% with a median survival of 16 days [4]. Clinical data
about patients with XDR TB in high income countries are
scarce. We therefore reviewed all cases of XDR TB detected
in our microbiology laboratory since 1997 and evaluated
the clinical course and the outcome of these cases.
Methods
Results of drug susceptibility testing (DST) for all myco-
bacterial isolates belonging to the mycobacterium tuber-
culosis complex (M. tuberculosis, M. bovis, M. africanum, M.
microti, M. canetti, M. caprae) have been recorded in the
electronic database of the Institute of Medical Microbiol-
ogy and Hygiene at Regensburg University since its imple-
mentation in 1997. We identified all isolates showing
resistance to INH and RMP and analysed the results of
drug susceptibility testing to second line drugs to identify
XDR TB strains according to the revised WHO criteria. We
retrieved data pertaining clinical course, treatment, and
outcome of these patients up to November 2006 from the
case records and communicated with the currently treat-
ing physicians. Results of DST performed in other German
laboratories have also been evaluated.
In our laboratory DST has been performed using the mod-
ified proportion method on Löwenstein-Jensen agar,
broth-based radiometric (BACTEC 460 system, Becton
Dickinson Diagnostic Systems, Sparks, MD).), and/or
nonradiometric testing methods (BACTEC MGIT 960,
Becton Dickinson Diagnostic Systems). Quality was con-
trolled internally according to DIN 58943 (DIN standard
of the German Institut for standardization) or to the man-
ufacturer' instructions, respectively, and externally by a
national quality assessment program.
For drugs used during treatment of XDR TB antitubercu-
lous drug dosing and dosing intervals is provided whenef-
fer different from WHO standard or when no WHO dose
recommendation is provided [6]. Treatment outcome was
categorised based on international standards [7]. For case
number 4, the only case for which information on cost of
in- and outpatient treatment was available, such data are
reported.
Results
In our Institute specimen from Regensburg University
hospital, from other local hospitals in the region of
Northern Bavaria, from other microbiology laboratories,
and from local health authorities are analysed.
From 1997 to 2006 in 2522 strains belonging to the M.
tuberculosis complex a DST was performed. 817 of these
isolates were sent to us for complete or partial DST only.
DST to first and second line antituberculous drugs were
performed according to clinical relevance and availability
of drugs at the time, when testing was performed. 2174
isolates were tested for MDR and in 470 strains at least
one second line drug has been tested.
During 1997 to 2006 112 isolates from 84 patients fulfill-
ing the criteria for multi drug resistance were identified.
Isolates from 15 of 71 patients tested revealed resistance
at least to one of the fluoroquinolones ofloxacin, cipro-
floxacin (Cfx) or moxifloxacin (Mxf). 19 of 71 patients
tested had isolates resistant to one of the i.v. second line
drugs: amikacin (Am, 15 of 53 patients tested) or kanamy-
cin (2 of 5 patients tested), and capreomycin (8 of 66
patients tested). 4 isolates fulfilled the revised criteria for
XDR-TB as stated above and case records of these patients
were analysed in detail. These XDR TB isolates were cul-
tured from samples gained from 1998 to 2003.
All patients immigrated to Germany, one from former
Yugoslavia and three from the Commonwealth of Inde-
pendent States (alliance of 11 former Soviet Republics),
where prevalence of MDR and XDR TB is particularly high
(Table 1). The available information about the antituber-
culous treatment in the patients' country of origin is very
limited.
All patients where treated for TB for 5.5 to 15 years and 1.9
to 2.5 years for XDR TB. Three received at least 4.5 years of
inhospital treatment in Germany for TB (Table 2). No
XDR TB patient was HIV-infected. All patients had exhib-
ited lack of compliance, three patients had to be treated in
Germanys only closed facility for tuberculosis treatment
repeatedly (Table 3). One patient with XDR TB died, one
patient had still open pulmonary TB at last contact and 2
patients were cured from XDR TB.
Patient 1 is a 40 year old asylum seeker, in whom TB was
diagnosed in 1995 in Georgia, where he had been treatedBMC Infectious Diseases 2008, 8:60 http://www.biomedcentral.com/1471-2334/8/60
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on an in- and outpatient-basis. In August 1997 at the time
of immigration to Germany he had open pulmonary TB
affecting both lungs with cavernous formation bilaterally.
Initial DST in Germany revealed MDR TB with additional
resistance to other first and second line drugs. Due to non-
compliance with the therapy he was admitted to the
closed facility. Radiographic findings improved but spu-
tum conversion was not achieved. After 10 months of
treatment, a right upper lobectomy and atypical left upper
lobectomy was performed, followed by a complicated
postoperative course. Several DST showed a very broad
spectrum of resistance without a chance of cure for any
available drug regimen at that time. As the patient urged
for an antituberculous drug therapy anyhow he received a
treatment with INH, RMP, ethambutol (EMB), and
pyrazinamide (PZA) for several months. In October 1999
a XDR strain was isolated. Despite resistance to Cfx, the
strain was sensitive to Mxf so a treatment was initiated
with Mxf, PZA (1500 mg/day) and clofazimine (50 mg/
day). A few months later clofazimine was substituted by
protionamide due to the latest DST. Protionamide was
stopped because of patient refusal in 2001. In February
2002 he returned to Georgia, and we have no information
about further treatment. At that time, after 4.5 years of
continuous inhospital treatment, sputum conversion still
had not been achieved.
Patient 2 is a 45 year old immigrant from Russia. He was
diagnosed with TB in 1992 and received prolonged treat-
ment, including 9 months of RMP monotherapy. He
arrived in Germany in July 1997 with MDR open pulmo-
nary TB with bilateral cavernous formations and right-
sided tuberculous otitis media. Initial empirical treatment
was adapted after DST, but sputum conversion was not
achieved and the patient had to be admitted to our closed
facility due to non-compliance the first time in April
1998. After almost three years of treatment sputum con-
version was achieved with a treatment regimen adapted to
the last DST including INH, EMB, Am, Mxf, p-aminosali-
cylic acid, terizidone. The patient had to be discharged
due to legal requirements albeit treating physicians were
unsure of the further compliance with the therapy. Shortly
Table 1: Epidemiologic factors, manifestations of tuberculosis
Patient 1 Patient 2 Patient 3 Patient 4
Country of Origin Georgia Russia, Sibiria Yugoslawia Russia
Risc Factors for TB smoking, alcohol abuse smoking, alcohol abuse smoking
HIV Status not infected not infected not infected not infected
Culture isolate M. tuberculosis M. tuberculosis M. tuberculosis M. tuberculosis
TB manifestation at time of 
immigration and at time of 
XDR TB diagnosis
reactivated open 
pulmonary tuberculosis 
with bilateral cavernous 
formations
reactivated open 
pulmonary tuberculosis 
with bilateral cavernous 
formations
reactivated open 
pulmonary tuberculosis 
with bilateral cavernous 
formations
reactivated open 
pulmonary tuberculosis 
affecting both lungs with a 
cavernous formation in the 
left upper lobe
Extrapulmonary 
manifestation
none right sided Otitis media none none
Table 2: Course of disease, outcome
Patient 1 Patient 2 Patient 3 Patient 4
First time TB diagnosis 1995 1992 1985 2001
Immigration Date August-97 July-97 March-92 March-03
Duration between TB and MDR TB diagnosis 2 years 5 years 12 years 2 years
Duration between MDR TB and XDR TB diagnosis 2 years 5 years 1.3 years concurrent
Duration between XDR TB diagnosis and end of antituberculous drug therapy in 
Germany
2.4 years 1.9 years 2 years 2.5 years
Overall length of inhospital treatment in Germany 4.5 years 6 years 6 years 11 months
Outcome treatment failure cure death cure
Last sputum cultures positive negative positive negative
Radiologic signs of activity present not present present not present
Known transmission of XDR strain to contacts no no no noBMC Infectious Diseases 2008, 8:60 http://www.biomedcentral.com/1471-2334/8/60
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thereafter he was readmitted again with open pulmonary
TB, probably due to non-compliance. XDR TB with resist-
ance to Cfx but sensitivity to Mxf was diagnosed in Janu-
ary 2002. In January 2003 right upper lobe resection was
performed and sputum conversion was again achieved
under a treatment of PZA, Am (500 mg/day until March
2003), Mxf, and linezolid (600 mg twice daily, reduced to
600 mg/day in March 2003). Two months later the patient
could be dismissed. In April 2003 he developed a left
sided spontaneous pneumothorax which did not respond
sufficiently to pleural drainage and an upper lobe and
lower lobe segmental resection was performed. Oral
antituberculous therapy (PZA, Mxf, and linezolid) was
continued until December 2003 and there were no signs
of reactivation of XDR TB since then.
Patient 3 was diagnosed with pulmonary TB in former
Yugoslavia in 1985 at age 38. Reactivation of TB was diag-
nosed and treated in Italy in November 1991. The patient
seeked asylum in Germany in March 1992 and received
inhospital treatment for open pulmonary TB and bilateral
cavernous transformation. Due to severe non-compliance
he was admitted to our closed facility in October 1992,
where he was treated until May 1993, when sputum con-
version was achieved. He was readmitted only three
months later, when sputum culture again turned positive.
Further closed ward treatment was necessary, but after
improvement of compliance, the patient could be dis-
charged in May 1995. After another inhospital treatment
1996 he was again admitted for open TB in summer 1997
and came to the closed ward for the third time in October
1997, where he remained until his death in April of the
year 2000. There was resistance to INH, EMB, and inter-
mediate susceptibility to RMP in 1992 already, but it took
until February 1997, when MDR TB diagnosis was defi-
nite. In May 1998 an XDR strain was isolated, only being
sensitive to streptomycin, p-aminosalicylic acid, clarithro-
mycin. The following drugs had been included in the dif-
ferent regimens before XDR TB was diagnosed: INH, RMP,
EMB, PZA, streptomycin, Am, capreomycin, Cfx,
ofloxacin, protionamide, p-aminosalicylic acid, cycloser-
ine, clofazimine, and doxycyclin.
During the following years, strains showing various resist-
ance patterns were isolated, but there was no curative
medical or surgical option, due to extensive resistance, the
patient's comorbidities and his non-compliance. He
received antituberculous treatment with various agents
(Table 3), but he died of progressive decompensated right
heart failure.
Patient 4 is a 45 year old immigrant, diagnosed with TB in
Russia at the end of 2001 and treated with an unknown
regimen for 5 – 6 months. Since mid 2002 he again had
fevers, chills, weight loss and he was admitted to hospital
immediately after arrival in Germany in spring 2003. Pul-
monary TB affecting both lungs with a cavernous forma-
tion in the left upper lobe was diagnosed and standard
treatment initiated. Initial DST revealed M. tuberculosis
fully sensitive to all first line drugs. After 6 months of
Table 3: Risk factors for resistance development, drug susceptibility testing, antituberculous therapy
Patient 1 Patient 2 Patient 3 Patient 4
Risk factors for resistance 
development:
Necessity of closed ward 
treatment
yes yes yes no
Antituberculous treatment 
before immigration
yes, regimen unknown yes, including 9 months of RMP 
monotherapy
yes, regimen unknown yes, regimen unknown
Drug susceptibility testing at 
time of Immigration:
Resistant INH, RMP, RFB, EMB, PZA, SM, 
Eto, Cs, Tsc, Clr, Cfz
INH, RMP, EMB, SM, Pto INH, EMB -
Intermediate PAS - - -
Susceptible Am, CM, Ofx PZA, Cs, Cfx RMP, PZA, SM INH, RMP, EMB, PZA, SM
Drug susceptibility testing at 
time of XDR Diagnosis:
Resistant INH, RMP, EMB, SM, Cm, Ofx, 
Eto, Pto, Cs, PAS, Tsc
INH, RMP, RFB, EMB, SM, CM, 
Cfx, Amx/Clv, Tsc
INH, RMP, RFB, EMB, PZA, Cm, 
Am, Ofx, Eto, Cs, Cfz, Tsc
INH, RMP, PZA, SM, Am, Cm, 
Cfx, Amx/Clv, Cfz, Tsc
Intermediate PZA Pto - -
Susceptible Mxf, Cfz PZA, Am, Mxf, Cs, Cfz, Lzd SM, PAS, Clr EMB, Mxf, Pto, Cs, PAS, Lzd
Antituberculous drugs used 
during therapy of XDR TB
PZA, Mxf, Pto, Cfz PZA, Am, Mxf, Lzd RFB, PZA, SM, Am, Cm, Ofx, 
Pto, Trd, PAS, Cfz, Amx/Clv, 
Clr, Doxycyclin
EMB, PZA, Am, Mxf, Cfx, Pto, 
Trd, Lzd
Non pharmacologic treatment right upper lobectomy and 
atypical left upper lobectomy
right upper lobe resection 01/03 
+ left upper lobe and left lower 
lobe segmental resection 04/03
left sided pneumonectomy
XDR extensively drug resistant, TB tuberculosis, INH isoniazid, RMP rifampicin, RFB rifabutin, EMB ethambutol, PZA pyrazinamide, SM 
streptomycin, Km kanamycin, Am amikacin, Cm capreomycin, Cfx ciprofloxacin, Ofx ofloxacin, Lfx levofloxacin, Mfx moxifloxacin, Eto ethionamide, 
Pto protionamide, Cs cycloserine, Trd terizidone, PAS p-aminosalicylic acid, Cfz clofazimine, Amx/Clv amoxicillin/clavulanate, Clr clarithromycin, 
Lzd linezolid, Tsc thiosemicarbazonBMC Infectious Diseases 2008, 8:60 http://www.biomedcentral.com/1471-2334/8/60
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treatment he was discharged without sputum conversion
and isolated at home. DST was repeated and finally
revealed an XDR TB strain. The patient was therefore again
admitted to hospital with massive excretion of bacilli and
empirical treatment with EMB, PZA, Am (1 g, 3 times per
week), Mxf, protionamide, terizidone (750 mg/day), and
linezolid (600 mg twice daily) was initiated. After 9 weeks
sputum conversion was achieved, but there was no radio-
logical improvement. As the left upper and lower lobes
were involved a left-sided pneumonectomy was per-
formed for definitive cure. While in November 2003 two
specimens showed XDR strains, further isolates showed
sensitivity to fluoroquinolones. Gastrointestinal drug tox-
icity led to withdrawal of PZA and protionamide after 4
months. Am was discontinued after 11 weeks because
DST revealed resistance. EMB had also to be withdrawn
due to drug toxicity. After 4.5 months developed a sensory
polyneuropathy affecting primarily his feet, but because
of being a mainstay of therapy, Linezolid was not discon-
tinued but its daily dose was reduced to 600 mg once
daily. Due to gastrointestinal toxicity Mxf was changed to
Cfx (1000 mg once daily). After 6 months the patient was
discharged and treated with Cxf, terizidone and linezolid
for a total of 24 months after surgery. Directly observed
therapy was organised through the local public health
department and later through the family to prevent
defaulting. 7 months after end of antituberculous treat-
ment no sign of reactivation could be found. The direct
medical costs in Germany were € 90.000 for inpatient
treatment and € 79.000 for outpatient antituberculous
drug therapy.
Systematic investigation of health care workers of all
patients and of household contacts of patient 4 did not
reveal transmission of XDR TB.
Discussion
Resistance of M. tuberculosis is increasingly reported.
Recently, data from a South African cohort of mostly HIV
infected XDR TB patients with a rapid and almost uni-
formly fatal course of disease was presented. Of the four
XDR TB patients we presented, none was HIV infected.
The long and complicated history of the disease and the
great impact of the non-compliance to antituberculous
measures and treatment are remarkable.
Epidemiologic data published by the Centers for Disease
Control and Prevention in 2006 showed a worldwide
increase of XDR TB according to the previous case defini-
tion from 2000 to 2004 [3]. In contrast to this, the facts
that contact investigation did not reveal transmission of
XDR TB and that we have not isolated another XDR strain
since 2004 suggest that XDR TB does not seem to spread
rapidly in our population. All patients were either hospi-
talised or home isolated and under strict control of the
local public health department at time of XDR TB diagno-
sis and none was discharged before sputum conversion.
While the incidence for tuberculosis in Germany
decreased from 13.6/100,000 in 1997 to 7,3/100,000 in
2005, the proportion of MDR isolates increased from
1.3% to 2,7% [8,9]. Referral bias is the most probable rea-
son for the higher proportion of MDR TB in our microbi-
ology laboratory, as our laboratory receives isolates to
perform DST for second line antituberculous drugs and
also receives specimen from hospitals specialised in TB
treatment.
A key feature in all of our patients seems to be the occur-
rence of mixed infection at some time point. In patient 4
at the time of XDR TB diagnosis two widely resistant
strains were isolated, one showing resistance and one
showing susceptibility to Cfx. The Cfx resistant strain was
isolated twice within a few days, and Cfx testing was per-
formed in Mycobacteria Growth Indicator Tube (MGIT,
Becton Dickinson Diagnostic Systems, critical concentra-
tion for ciprofloxacin susceptibility: 2 mg/l), so misinter-
pretation seems to be unlikely. Our interpretation is that
in this case there had been two strains, one XDR strain and
one MDR strain still sensitive to fluoroquinolones.
In recent years several reports about heteroresistance (i.e.
a mixture of resistant and susceptible subpupulations in
the same culture) have shown that mixed infection is a
valid phenomenon in clinical tuberculosis and is not
uncommon [10-14].
Mixed infection can explain the fact, that in the patients
presented the occurrence of resistance to a specific drug
can not always be deduced by the initial DST and the
antituberculous therapy given in the meantime. In these
cases a mixed infection with an already resistant strain
may have been obscured by the conventional methods of
TB culture and DST.
During the long course of disease in patients 1 to 3 DST
sometimes revealed isolates showing susceptibility to
antituberculous drugs previously tested resistant. It has
been hypothesised that the use of second line drugs leads
to re-emergence of drug susceptible strains in patients
with mixed infections [15].
If the mixed infection is due to unrelated strains or due to
one strain with different resistance patterns remains
unclear, as DNA fingerprinting or other subtyping data
addressing this question is not available.
While WHO guidelines recommend the use of at least four
active drugs for treatment of MDR-TB, this is often not
possible for XDR-TB [6]. Individual regimens have beenBMC Infectious Diseases 2008, 8:60 http://www.biomedcentral.com/1471-2334/8/60
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used in the patients presented. With only two patients
cured from XDR tuberculosis outcomes are far from opti-
mal. Cure was only achieved in patients who where oper-
ated and who had a fluoroquinolone as a therapeutic
option. This underlines the impact of this drug class for
treatment success in MDR and XDR TB.
Another important factor for successful treatment of
resistant tuberculosis is directly observed therapy. While
the current structures worked well in patient 4, poor
adherence during outpatient treatment after discharge
from the closed facility was an important factor for further
resistance development in patients 2 and 3. This case
series demonstrates that M. tuberculosis does not only
develop extensive drug resistance in countries with subop-
timal health care resources but also in our high income
setting. Therefore, maintenance of structures for TB con-
trol and improvement of deficits in outpatient treatment
of non-compliant patients is mandatory, even when the
incidence of TB in industrialised countries remains low or
even declining. As this may afford additional resources
political commitment is necessary.
Our four cases also demonstrate the tremendous impact
of XDR TB on quality of life and on health care resources.
Three of our patients were treated in inpatient settings for
4.5 to 6 years. Not only the total length of hospital stay
but also the prolonged administration of expensive and
toxic second line agents, operations, non-pharmacologi-
cal treatment, the use of administrative and legal
resources, and last but not least the high expenses of a
closed ward treatment are all contributing to the very high
cost of treatment of XDR TB. Because of the extremely
long course of disease, multiple treatment changes and
the many health care providers involved reliable cost esti-
mation is very difficult in patients 1 to 3. Still, in patient
4, who had by far the shortest course, treatment cost
exceeded € 170,000.
Several reports have shown that MDR strains are transmit-
ted effectively from person to person [1]. 55% of patients
from the South African cohort had no previous treatment.
Additionally, health care workers were affected. This dem-
onstrates that extensive drug resistance does not diminish
the contagiousness of the involved strains. Fortunately
systematic contact investigation did not reveal transmis-
sion of an XDR strain from our reported patients to close
contacts or health care professionals. Consequent imple-
mentation of isolation according to the recommendations
of the German Central Committee against Tuberculosis,
low HIV-prevalence and the medical resources of a high
income country may have contributed to this finding [16].
The nightmare of patients eluding public health care
measures are currently discussed in the context of a case
provoking media attention and public outrage in the USA
[17].
Conclusion
In this report we present four cases with XDR TB in a high
income country. Cases of XDR TB have been treated in our
region for several years and fortunately it has not gained
such a tremendous impact as suggested by the data from
the recent report from HIV infected patients from South
Africa. But even in a high income country XDR TB has a
tremendous impact on quality of live, outcome and the
expense of medical resources. Therefore, all reasonable
efforts to prevent the development and the spread of XDR
TB must be made and maintained.
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